Immuno-Oncology | Specialty

Dr. Heymach on Nivolumab for Lung Cancer

April 14th 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses efficacy findings with nivolumab (Opdivo) results for patients with metastatic lung cancer.

Dr. Wilky on Immunotherapy Trial in Sarcoma

April 13th 2017

Breelyn Wilky, MD, an associate professor of Medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, discusses the design of a phase II trial investigating concurrent axitinib (Inlyta) and pembrolizumab (Keytruda) in patients with advanced alveolar soft part sarcoma and other soft tissue sarcomas.

Dr. Quinn on the Future of Treatments for RCC

April 13th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on the future of treatments for patients with renal cell carcinoma (RCC).

Dr. Gomella on Ongoing Trials of Immunotherapy in Bladder Cancer

April 12th 2017

Leonard Gomella, MD, professor, chair, Department of Oncology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses ongoing trials of immunotherapy for patients with bladder cancer.

Dr. Gordon on Toxicities With Immunotherapy in Osteosarcoma

April 12th 2017

Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.

Survival Gain With Higher Ipilimumab Dose Offers Opportunity for Some Melanoma Patients

April 11th 2017

Patients with stage III or IV melanoma assigned to 10 mg/kg ipilimumab (Yervoy) lived longer than patients assigned to a lower dose of the anti-CTLA-4 anticlonal antibody, but at the cost of greater toxicity.

Dr. Quinn on Combinations of Targeted Therapy in RCC

April 11th 2017

David I. Quinn, MD, MBBS, associate professor of Medicine, medical director of USC Norris Cancer Hospital, on combinations of targeted therapies for patients with renal cell carcinoma (RCC).

Dr. Slovin on Immunotherapy Agents for Prostate Cancer

April 11th 2017

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses potential immunotherapy agents for patients with prostate cancer.

Nivolumab Effective in Advanced Anal Cancer

April 10th 2017

According to findings from a single-arm phase II trial, treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in an overall response rate of 24.3% in previously treated patients with squamous cell carcinoma of the anal canal.

Dr. Costin on Frontline Immunotherapy for Patients With NSCLC

April 8th 2017

Daniel Costin, MD, hematology and oncology, White Plains Hospital, discusses the potential with immunotherapy agents in the frontline setting as treatment for patients with non–small cell lung cancer (NSCLC).

RCC Advances Shake Up Drug Choices

April 7th 2017

Axitinib was a promising newcomer in the renal cell carcinoma field when it was introduced as a second-line therapy 5 years ago. Now it is being displaced by newer therapies, a development that may serve as a harbinger for the evolution of treatment patterns in other tumor types with a bounty of novel agents.

Pembrolizumab Impresses in Heavily Pretreated Head and Neck Cancer

April 7th 2017

Pembrolizumab has shown durable, clinically significant responses in patients with locally advanced head and neck cancer who are refractory to platinum-based chemotherapy and cetuximab, according to results from the single-arm, phase II KEYNOTE-055 study.

Dr. Heymach Discusses the CheckMate-026 Study in Lung Cancer

April 7th 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the CheckMate-026 trial in lung cancer.

New Checkpoint Inhibitor Approach Proposed in Prostate Cancer

April 7th 2017

Padmanee Sharma, MD, PhD, discusses the significance of the VISTA immune-checkpoint pathway in prostate cancer, and her proposed novel immunotherapy approach for patients with these tumors.

Future of Immunotherapy Use in Lung Cancer

April 6th 2017

Atezolizumab Versus Other Immunotherapy Options

April 6th 2017

FDA Approval of Atezolizumab for NSCLC

April 6th 2017

Immunotherapy in Chemorefractory Lung Cancer

April 6th 2017

Historic Perspective on Immunotherapy in Lung Cancer

April 6th 2017

Dr. Wolchok on Weighing Risk and Benefit of Nivolumab/Ipilimumab Combo in Melanoma

April 5th 2017

Jedd D. Wolchok, MD, PhD, chief, Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses weighing the overall survival (OS) benefit with the increased risk of toxicities seen with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma.